Download PDF
Journal of Pediatric Neurology 2017; 15(03): 123-128
DOI: 10.1055/s-0037-1601445
Review Article
Georg Thieme Verlag KG Stuttgart · New York

New Perspectives in Autism Spectrum Disorder associated with Tuberous Sclerosis

Arianna Benvenuto
1   Child Neurology and Psychiatry Unit, Department of System Medicine, University of Rome Tor Vergata, Roma, Italy
,
Martina Siracusano
1   Child Neurology and Psychiatry Unit, Department of System Medicine, University of Rome Tor Vergata, Roma, Italy
,
Federica Graziola
1   Child Neurology and Psychiatry Unit, Department of System Medicine, University of Rome Tor Vergata, Roma, Italy
,
Romina Moavero
1   Child Neurology and Psychiatry Unit, Department of System Medicine, University of Rome Tor Vergata, Roma, Italy
2   Department of Neuroscience and Neurorehabilitation, Bambino, Gesù Children's Hospital, IRCCS, Rome, Italy
,
Luigi Mazzone
1   Child Neurology and Psychiatry Unit, Department of System Medicine, University of Rome Tor Vergata, Roma, Italy
2   Department of Neuroscience and Neurorehabilitation, Bambino, Gesù Children's Hospital, IRCCS, Rome, Italy
,
Leonardo Emberti Gialloreti
3   Department of Biomedicine and Prevention, University of Rome, University of Rome Tor Vergata, Rome, Italy
4   Centre for Communication and Neurorehabilitation Research-CNAPP, Rome, Italy
,
Paolo Curatolo
1   Child Neurology and Psychiatry Unit, Department of System Medicine, University of Rome Tor Vergata, Roma, Italy
› Author Affiliations
Further Information

Publication History

20 December 2016

12 February 2017

Publication Date:
04 April 2017 (online)

    Permissions and Reprints

Abstract

Recent advances in molecular genetics and preclinical studies of tuberous sclerosis complex (TSC) have helped to better understand the pathophysiology of TSC-related autism spectrum disorder (ASD). Furthermore, developmental studies have shown that infants with TSC begin to diverge from the neurotypical trajectories at the age of 6 months. Early abnormalities are often characterized by a delay in nonverbal cognitive skills, such as fine motor and visual reception domains followed by qualitative impairment of social communication. The expanding possibilities of an early diagnosis of TSC should increasingly allow the prompt identification of a population of infants at high risk for developing ASD. A presymptomatic diagnosis of TSC could facilitate not only the prospective investigation of developmental trajectories and early markers of ASD but also the evaluation of the efficacy of early interventions. Early identification of infants at high-risk for ASD, such as TSC infants, can allow designing individualized treatment strategies to address deficits in specific developmental domains associated with autism. The involvement of mammalian target of rapamycin (mTOR) in determining the behavioral phenotypes associated with TSC led to the hypothesis that mTOR inhibitors could also have a benefit on ASD symptoms. After the promising results from preclinical studies administrating rapamycin, clinical trials studying mTOR inhibitors are now undergoing.

Keywords

tuberous sclerosis complex - epilepsy - autism spectrum disorder - early intervention - mTOR inhibitors - parent-mediated intervention - predictors - risk factors
 

  • References

  • 1 van Slegtenhorst M, de Hoogt R, Hermans C. , et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277 (5327): 805-808
    CrossrefPubMedGoogle Scholar
  • 2 European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75 (07) 1305-1315
    CrossrefPubMedGoogle Scholar
  • 3 Napolioni V, Moavero R, Curatolo P. Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain Dev 2009; 31 (02) 104-113
    CrossrefPubMedGoogle Scholar
  • 4 Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015; 14 (07) 733-745
    CrossrefPubMedGoogle Scholar
  • 5 Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51 (07) 1236-1241
    Google Scholar
  • 6 American Psychiatric Association. Report of DSM-5 Proposed Criteria for Autism Spectrum Disorder. Arlington, VA: American Psychiatric Publishing; 2013
    Google Scholar
  • 7 Kim YS, Leventhal BL, Koh YJ. , et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011; 168 (09) 904-912
    CrossrefPubMedGoogle Scholar
  • 8 Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet 2014; 383 (9920): 896-910
    CrossrefPubMedGoogle Scholar
  • 9 Critchley M, Earl C. Tuberous sclerosis and allied conditions. Brain 1932; 55: 311-346
    CrossrefPubMedGoogle Scholar
  • 10 Wong V. Study of the relationship between tuberous sclerosis complex and autistic disorder. J Child Neurol 2006; 21 (03) 199-204
    PubMedGoogle Scholar
  • 11 Numis AL, Major P, Montenegro MA, Muzykewicz DA, Pulsifer MB, Thiele EA. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology 2011; 76 (11) 981-987
    CrossrefPubMedGoogle Scholar
  • 12 Goorden SM, van Woerden GM, van der Weerd L, Cheadle JP, Elgersma Y. Cognitive deficits in Tsc1+/− mice in the absence of cerebral lesions and seizures. Ann Neurol 2007; 62 (06) 648-655
    CrossrefPubMedGoogle Scholar
  • 13 Ehninger D, de Vries PJ, Silva AJ. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res 2009; 53 (10) 838-851
    CrossrefPubMedGoogle Scholar
  • 14 Curatolo P, Napolioni V, Moavero R. Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment. J Child Neurol 2010; 25 (07) 873-880
    CrossrefPubMedGoogle Scholar
  • 15 Zeng LH, Ouyang Y, Gazit V. , et al. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2007; 28 (02) 184-196
    CrossrefPubMedGoogle Scholar
  • 16 Bourgeron T. A synaptic trek to autism. Curr Opin Neurobiol 2009; 19 (02) 231-234
    CrossrefPubMedGoogle Scholar
  • 17 Jansen FE, Vincken KL, Algra A. , et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology 2008; 70 (12) 916-923
    CrossrefPubMedGoogle Scholar
  • 18 Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol 2010; 14 (02) 146-149
    CrossrefPubMedGoogle Scholar
  • 19 Cusmai R, Moavero R, Bombardieri R, Vigevano F, Curatolo P. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav 2011; 22 (04) 735-739
    CrossrefPubMedGoogle Scholar
  • 20 Curatolo P, Aronica E, Jansen A. , et al. Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC. Eur J Paediatr Neurol 2016; 20 (02) 203-211
    CrossrefPubMedGoogle Scholar
  • 21 Zhang B, McDaniel SS, Rensing NR, Wong M. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One 2013; 8 (02) e57445 Doi: 10.1371/journal.pone.0057445
    CrossrefPubMedGoogle Scholar
  • 22 Jóźwiak S, Nabbout R, Curatolo P. ; participants of the TSC Consensus Meeting for SEGA and Epilepsy Management. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol 2013; 17 (04) 348-352
    CrossrefPubMedGoogle Scholar
  • 23 Wu JY, Peters JM, Goyal M. , et al. Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants. Pediatr Neurol 2016; 54: 29-34
    CrossrefPubMedGoogle Scholar
  • 24 Jóźwiak S, Kotulska K, Domańska-Pakieła D. , et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 2011; 15 (05) 424-431
    CrossrefPubMedGoogle Scholar
  • 25 Zeng LH, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 2011; 20 (03) 445-454
    CrossrefPubMedGoogle Scholar
  • 26 Cusmai R, Chiron C, Curatolo P, Dulac O, Tran-Dinh S. Topographic comparative study of magnetic resonance imaging and electroencephalography in 34 children with tuberous sclerosis. Epilepsia 1990; 31 (06) 747-755
    CrossrefPubMedGoogle Scholar
  • 27 Bolton PF, Park RJ, Higgins JN, Griffiths PD, Pickles A. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain 2002; 125 (Pt 6): 1247-1255
    CrossrefPubMedGoogle Scholar
  • 28 Dabora SL, Jozwiak S, Franz DN. , et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68 (01) 64-80
    CrossrefPubMedGoogle Scholar
  • 29 Moavero R, Napolitano A, Cusmai R. , et al. White matter disruption is associated with persistent seizures in tuberous sclerosis complex. Epilepsy Behav 2016; 60: 63-67
    CrossrefPubMedGoogle Scholar
  • 30 Peters JM, Sahin M, Vogel-Farley VK. , et al. Loss of white matter microstructural integrity is associated with adverse neurological outcome in tuberous sclerosis complex. Acad Radiol 2012; 19 (01) 17-25
    CrossrefPubMedGoogle Scholar
  • 31 Spurling Jeste S, Wu JY, Senturk D. , et al. Early developmental trajectories associated with ASD in infants with tuberous sclerosis complex. Neurology 2014; 83 (02) 160-168
    CrossrefPubMedGoogle Scholar
  • 32 Jeste SS, Varcin KJ, Hellemann GS. , et al. Symptom profiles of autism spectrum disorder in tuberous sclerosis complex. Neurology 2016; 87 (08) 766-772
    CrossrefPubMedGoogle Scholar
  • 33 Woo CC, Donnelly JH, Steinberg-Epstein R, Leon M. Environmental enrichment as a therapy for autism: A clinical trial replication and extension. Behav Neurosci 2015; 129 (04) 412-422
    CrossrefPubMedGoogle Scholar
  • 34 Favre MR, La Mendola D, Meystre J. , et al. Predictable enriched environment prevents development of hyper-emotionality in the VPA rat model of autism. Front Neurosci 2015; 9: 127 Doi: 10.3389/fnins.2015.00127
    PubMedGoogle Scholar
  • 35 Koegel L, Singh A, Koegel R, Hollingsworth J, Bradshaw J. Assessing and improving early social engagements in infants. J Posit Behav Interv 2014; 16 (02) 69-80
    CrossrefPubMedGoogle Scholar
  • 36 Rogers SJ, Vismara L, Wagner AL, McCormick C, Young G, Ozonoff S. Autism treatment in the first year of life: a pilot study of infant start, a parent-implemented intervention for symptomatic infants. J Autism Dev Disord 2014; 44 (12) 2981-2995
    CrossrefPubMedGoogle Scholar
  • 37 Green J, Charman T, McConachie H. , et al; PACT Consortium. Parent-mediated communication-focused treatment in children with autism (PACT): a randomised controlled trial. Lancet 2010; 375 (9732): 2152-2160
    CrossrefPubMedGoogle Scholar
  • 38 Ehninger D, Han S, Shilyansky C. , et al. Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis. Nat Med 2008; 14 (08) 843-848
    CrossrefPubMedGoogle Scholar
  • 39 Talos DM, Sun H, Zhou X. , et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One 2012; 7 (05) e35885 Doi: 10.1371/journal.pone.0035885
    CrossrefPubMedGoogle Scholar
  • 40 Kilincaslan A, Kok BE, Tekturk P, Yalcinkaya C, Ozkara C, Yapici Z. Beneficial Effects of Everolimus on Autism and Attention-Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex. J Child Adolesc Psychopharmacol 2016; DOI: 10.1089/cap.2016.0100.
    PubMedGoogle Scholar